What are the immediate complications following radioiodine (I-131) therapy for a single hyperfunctioning thyroid nodule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Immediate complications following radioiodine therapy for a single hyperactive thyroid nodule are typically mild and self-limiting, including radiation thyroiditis, transient hyperthyroidism, and radiation sialadenitis, which can be managed with supportive care and medications such as NSAIDs, beta-blockers, and sialagogues. These complications are generally short-term and resolve as the radioactive iodine is cleared from the body. Radiation thyroiditis, occurring in 1-5% of patients, can be managed with NSAIDs like ibuprofen 400-600mg three times daily for 3-5 days 1. Transient worsening of hyperthyroidism may occur due to release of preformed thyroid hormones from damaged follicular cells, usually within 7-10 days post-treatment, and can be controlled with beta-blockers such as propranolol 20-40mg three times daily. Radiation sialadenitis affects 10-30% of patients, causing painful swelling of salivary glands, dry mouth, and altered taste, and can be managed with hydration, sialagogues like sugar-free lemon candies, and analgesics. Rarely, patients may experience radiation gastritis with nausea or vomiting, which typically resolves within 48 hours and can be managed with antiemetics. Allergic reactions to radioiodine are extremely rare. The management of these complications is crucial to improve the quality of life and reduce morbidity and mortality in patients undergoing radioiodine therapy for a single hyperactive thyroid nodule. Key considerations in the management of these complications include:

  • Monitoring for signs and symptoms of radiation thyroiditis, transient hyperthyroidism, and radiation sialadenitis
  • Providing supportive care and medications as needed to manage these complications
  • Educating patients on the potential complications of radioiodine therapy and the importance of follow-up care. It is essential to note that the evidence from the study 1 provides guidance on the management of complications following radioiodine therapy, but it is crucial to consider the individual patient's needs and medical history when developing a treatment plan.

From the Research

Immediate Complications Following Radioiodine Therapy

  • The studies provided do not directly address immediate complications following radioiodine therapy for a single hyperactive thyroid nodule 2, 3, 4, 5, 6.
  • However, it can be inferred that radioiodine therapy is generally well-tolerated, but may cause some side effects such as exacerbation of hyperthyroidism if not preceded by pharmacological normalization of thyroid function 3.
  • Additionally, radioiodine therapy may increase the inflammatory process and exacerbate ophthalmological symptoms in patients with thyroid-associated orbitopathy, although this is not considered a contraindication for treatment 3.
  • Other potential complications of radioiodine therapy, such as radiation exposure to others, can be mitigated with proper radiation protection precautions 5.

Alternative Treatments

  • Alternative treatments for hyperactive thyroid nodules, such as radiofrequency ablation (RFA), may have a lower risk of permanent hypothyroidism compared to radioiodine therapy 4.
  • Interstitial laser photocoagulation (ILP) is another alternative treatment that has been shown to be effective in reducing thyroid nodule volume, although it may be inferior to radioiodine therapy in normalizing serum TSH levels 6.

Considerations for Radioiodine Therapy

  • Radioiodine therapy should be preceded by pharmacological normalization of thyroid function to avoid exacerbation of hyperthyroidism 3.
  • Patients should be properly prepared for radioiodine therapy, including reducing iodine intake and achieving high levels of thyroid-stimulating hormone prior to treatment 5.
  • Radiation protection precautions should be taken to protect others from unnecessary radiation exposure following treatment 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Radioiodine therapy of hyperfunctioning thyroid nodules: usefulness of an implemented dose calculation algorithm allowing reduction of radioiodine amount.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.